摘要
目的比较替吉奥(维康达,S-1)分别联合奥沙利铂(OXA)(SOX方案)、多西他赛(TXT)(DS方案)与顺铂(DDP)(SP方案)一线治疗进展期胃癌(AGC)的临床疗效与毒副反应。方法选取63例AGC患者,随机分为A、B、C 3组,每组21例,分别接受SOX方案、DS方案和SP方案治疗,评价3个周期化疗后的疗效及毒副反应。结果 A、B、C 3组患者近期有效率(RR)分别是57%,52%和43%,3组近期有效率比较无显著性差异(P均>0.05);疾病控制率(DCR)分别为81%,76%和76%,3组比较无显著性差异(P均>0.05);Ⅲ～Ⅳ度白细胞下降发生率DS方案组显著高于其他2组(P均<0.05);Ⅲ～Ⅳ度恶心、呕吐反应发生率SP方案显著高于其他2组(P均<0.05)。其他相关毒副反应未见显著性差异(P均>0.05)。结论 SOX方案、DS方案和SP方案一线治疗AGC有较好的临床疗效,DS方案有较高的骨髓毒性,SP方案有较高的消化道反应,但毒副反应均可耐受。
Objective It is to investigate the efficacy and toxicity of combination chemotherapy of S - 1 plus oxaliplatin （ SOX regiment） , S - 1 plus docetaxel （ DS regiment） and S - 1 plus cisplatin （ SP regiment） in patients with advanced gas- tric cancer （AGC） for first-line treatment. Methods Sixty-three patients with AGC were randomly divided into three groups and 21 cases in each groups, who underwent SOX regiment in Group A, DS regiment in Group B and SP regiment in Group C. All patients were treated more than three chemotherapy cycles. The efficacy and toxic side effects were assessed. Results The overall response rates （RR） in Group A, B and C were 57% , 52% and 43% respectively; and the disease control rates （DCR） were 81% , 76% and 76% respectively. There was no significant difference among three groups （P 〉 0.05 ）. Ⅲ to Ⅳ grade leucopenia for DS regimen was higher than the other two groups （ P 〈 0.05 ）. Ⅲ to IV grade nausea and vomiting for SP regimen was higher than SOX regimen and DS regimen （ P 〈 O. 05 ）. Conclusion SOX, DS and SP regimen in the first-line treatment of AGC has good clinical efficacy and tolerability. DS regiment has higher hematological toxicities and SP regiment has higher nausea and vomiting incidence.
出处
《现代中西医结合杂志》
CAS
2012年第24期2628-2630,共3页
Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词
维康达
奥沙利铂
紫杉醇
顺铂
进展期胃癌
化疗
S-1
Oxaliplatin
Docetaxel
Cisplatin
advanced gastric cancer
chemotherapy
